CLINICAL_TRIALS
trial_result
· 2024-03-12
Clinical Trial Update: The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients [Phase 4]
Summary
Phase 4 clinical trial update on tafamidis meglumine for transthyretin amyloid polyneuropathy has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Transthyretin Amyloid Polyneuropathy (ATTR-PN) | Phase 4 | Status: COMPLETED | Results posted: 2024-03-12